Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters...
Read More Details
Finally We wish PressBee provided you with enough information of ( Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 )
Also on site :
- I Tried 15 Different Brands of Potato Chips and Found a New Favorite
- Paris arrested Telegram founder to meddle in Romanian election — Moscow
- Popular Actress, 40, Returns for First Red Carpet Since Husband's Death